Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microreactors as new tools for drug discovery and development.

S Y F Wong-Hawkes1, J C Matteo, B H Warrington

  • 1BB Consultants Ltd, 45 The Drive, SG14 3DE Hertford, UK.

Ernst Schering Foundation Symposium Proceedings
|August 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of intravenous mixed micelle phytomenadione (vitamin K1) and traditional therapies for the treatment of anticoagulant rodenticide toxicosis in dogs and cats: a retrospective study.

Australian veterinary journal·2025
Same author

Case of Great Hypertrophy of the Heart and Open Foramen Ovale, without Cyanosis.

Medical examiner (Philadelphia, Pa.)·2023
Same author

Rupture of the gastrocnemius muscle at its distal musculotendinous junction: conservative treatment and outcomes in 11 dogs.

New Zealand veterinary journal·2023
Same author

Practical Hints.

The Dental register·2021
Same author

Amalgam.

The Dental register·2021
Same author

Treatment of Dental Pulp Preparatory to Plugging.

The Dental register·2021
Same journal

Inhibiting Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating system in cancer.

Ernst Schering Foundation symposium proceedings·2009
Same journal

Dissecting roles of ubiquitination in the p53 pathway.

Ernst Schering Foundation symposium proceedings·2009
Same journal

Crosstalk between the SUMO and ubiquitin pathways.

Ernst Schering Foundation symposium proceedings·2009
Same journal

The ubiquitin system in health and disease. Preface.

Ernst Schering Foundation symposium proceedings·2009
Same journal

Approaches to discovering drugs that regulate E3 ubiquitin ligases.

Ernst Schering Foundation symposium proceedings·2009
Same journal

Regulation of T cell differentiation and allergic responses by the E3 ubiquitin ligase itch.

Ernst Schering Foundation symposium proceedings·2009
See all related articles

Flow microreactors offer flexible, safer pharmaceutical production and accelerate drug discovery. This technology enables rapid screening of chemical compounds and faster development of new medicines.

Area of Science:

  • Chemical Engineering
  • Pharmaceutical Sciences
  • Drug Discovery

Background:

  • Traditional large-scale batch reactors limit flexibility and safety in pharmaceutical production.
  • Flow microreactors offer enhanced control and safety for fine chemical synthesis.
  • Pharmaceutical research and development (R&D) requires efficient methods for lead compound identification and optimization.

Purpose of the Study:

  • To describe the application of microreactors in pharmaceutical R&D for accelerated drug discovery.
  • To present an integrated micro-scaled chemical synthesis and bioassay system for rapid lead optimization.
  • To highlight the use of microreactors for point-of-use synthesis of positron emission tomography (PET) ligands.

Main Methods:

  • Utilizing microreactors to create an integrated micro-scaled chemical synthesis and bioassay system.

Related Experiment Videos

  • Implementing fast-cycling iterative searches within diverse chemical space.
  • Employing microreactors for the down-scaled and accelerated synthesis of short-lived biomarkers (PET ligands).

    • Main Results:

    • Demonstrated enhanced and inherently safer production protocols using microreactors.
    • Developed a system for rapid discovery and optimization of novel drug leads.
    • Achieved significant down-scaling and acceleration in the synthesis of PET ligands.

    Conclusions:

    • Microreactors provide a flexible and safer alternative to batch reactors in pharmaceutical production.
    • Integrated microreactor systems enhance the efficiency of drug discovery and lead optimization.
    • Accelerated synthesis of PET ligands using microreactors can reduce drug approval timelines and resource requirements.